

17 March 2026

Convatec Group Plc
("Convatec" or "the Company")

Notice of Annual General Meeting

The Company's annual general meeting (the "Annual General Meeting") will take place at 14:00 (UK time) on Thursday 21 May 2026 at the Company's offices at 20 Eastbourne Terrace, London W2 6LG.

The Company's Notice of Annual General Meeting and Form of Proxy including details of how shareholders can appoint a proxy, are being sent to shareholders today and have been submitted to the National Storage Mechanism in accordance with UK Listing Rule 6.4.1 of the Financial Conduct Authority. These documents will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

A copy of the Company's Notice of Annual General Meeting can be accessed on the Company's website at www.convatecgroup.com.

This announcement is made in accordance with DTR 6.3.5R(1A).

Enquiries

James Kerton, Company Secretary
Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 3.1 Additional regulated information required to be disclosed under the laws of the United Kingdom

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over 2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit <http://www.convatecgroup.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAUBSURNRUOAAAR